Diabetic retinopathy and diabetic macular edema are significant complications of diabetes that can lead to vision loss. Early detection through ultra-widefield fundus imaging enhances patient outcomes but presents challenges in image quality and analysis scale. This paper introduces deep learning solutions for automated UWF image analysis within the framework of the MICCAI 2024 UWF4DR challenge. We detail methods and results across three tasks: image quality assessment, detection of referable DR, and identification of DME. Employing advanced convolutional neural network architectures such as EfficientNet and ResNet, along with preprocessing and augmentation strategies, our models demonstrate robust performance in these tasks. Results indicate that deep learning can significantly aid in the automated analysis of UWF images, potentially improving the efficiency and accuracy of DR and DME detection in clinical settings.

The nation's leading association that fights against diabetes released a new set of clinical standards that for the first time include the use of autonomous artificial intelligence (AI). The American Diabetes Association (ADA)'s 2020 Standards of Medical Care in Diabetes states that, "AI systems that detect more than mild diabetic retinopathy and diabetic macular edema authorized for use by the FDA represent an alternative to traditional screening approaches." To date, IDx-DR is the first and only FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. It is currently in use at a number of large health systems that each serve tens of thousands of people with diabetes and have struggled to implement diabetic retinopathy eye exams at scale for their large diabetes population. "The ADA's inclusion of our technology in its Standards of Care marks a significant move toward mainstream adoption of autonomous AI in clinical care," said Michael Abramoff, MD, PhD, Founder and Executive Chairman at IDx. "Our early customers are visionary leaders who foresaw that autonomous AI would one day become a standard of care for diabetic retinopathy screening, and taking that leap is paying off for them. Already, health systems that are using IDx-DR have experienced significant improvements in accessibility, efficiency and compliance rates, unleashing massive potential for cost savings and improved patient outcomes."